Last quarter (Q4 2023), Assertio Therapeutics's total revenue was $32.98M, a decrease of -34.49% from the same quarter last year. In Q4, Assertio Therapeutics's net income was $-57.38M. See Assertio Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 152.07M	$ 152.07M	$ 156.23M	$ 111.01M	$ 106.28M	$ 229.50M
Cost of Revenue	$ 21.55M	$ 27.02M	$ 18.75M	$ -15.83M	$ 19.87M	$ 9.51M
Gross Profit	$ 130.52M	$ 125.05M	$ 137.49M	$ 95.18M	$ 86.40M	$ 220.00M
Operating Expense	$ 109.01M	$ 109.01M	$ 79.39M	$ 84.67M	$ 133.32M	$ 220.75M
Operating Income	$ -228.66M	$ -243.54M	$ 39.41M	$ 10.51M	$ -46.92M	$ -747.00K
Net Non Operating Interest Income Expense	$ -13.30M	$ -13.30M	$ -7.96M	$ -10.22M	$ -15.93M	$ -58.39M
Other Income Expense	$ 256.79M	$ 251.32M	$ 18.96M	$ -243.00K	$ 17.33M	$ -163.35M
Pretax Income	$ -254.05M	$ -254.05M	$ 31.17M	$ -553.00K	$ -45.51M	$ -222.48M
Tax Provision	$ 77.89M	$ 77.89M	$ -78.46M	$ 728.00K	$ -17.37M	$ -5.28M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -331.94M	$ -331.94M	$ 109.63M	$ -1.28M	$ -28.14M	$ -217.20M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 130.56M	$ 136.03M	$ 79.39M	$ 68.84M	$ 153.19M	$ 230.25M
Net Income From Continuing And Discontinued Operation	$ -331.94M	$ -331.94M	$ 109.63M	$ -1.28M	$ -28.14M	$ -217.20M
Normalized Income	$ 54.13M	$ 58.87M	-	-	$ -40.86M	$ -53.88M
Interest Expense	-	-	-	-	$ 15.93M	$ 34.63M
EBIT	$ -240.76M	$ -240.76M	$ 39.13M	$ 9.67M	$ -29.59M	$ -187.86M
EBITDA	$ -212.07M	$ -212.07M	$ 72.83M	$ 38.94M	$ -3.16M	$ -84.91M

Currency in USD

Assertio Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing